Check Out Our Up Coming Webinar and Events

Do you want to know more about the industry is evolving? What progress has been made and what challenges remain? Join us to learn more.

Up Coming Webinar and Events Webinar Date: May 18, 2022 Time: 2pm ET / 11am PT Join us to learn how healthcare organizations can more easily triage the patient's care needs, determine the best care setting – in-person care, virtual care, home care, or hybrid care – and drive follow up.  Register Now Not able to attend? We recommend you still register and you will receive an email with how to access the recording of the event! INVEST Events 2022 1 Day of High-Quality Virtual Meetings Around Digital Innovation   MedCity INVEST PharmaTech 2022 is a complimentary program dedicated to exploring the next chapter of the biopharma industry. Discussions will explore how pharma companies leverage digital innovations to achieve greater success and transform the lives of patients. Register Now 1 Day of High-Quality, In-Person Meetings Around Digital Health Technology   Register by June 3rd and save $200 with the Extreme Early Bird Rate    Join us in Dallas for MedCity INVEST Digital Health on Wednesday, September 28.   Don't miss out on this valuable opportunity to meet and discuss the latest trends and opportunities, and showcase how your company is changing the future of digital health.  Register Now MedCity News, 611 Broadway, New York, NY 10012, United States, 2123341871 Unsubscribe Manage preferences

Potential blockbuster Bristol Myers cardio drug gets FDA nod

The latest stories trending on MedCity News.

Not rendering correctly? View this email as a web page here. TOP STORIES Potential blockbuster BMS cardio drug gets FDA nod, first in rare heart disease Bristol Myers Squibb drug Camzyos has FDA approval for treating obstructive hypertrophic cardiomyopathy, a rare and potentially fatal heart disorder. The drug is projected to become a blockbuster seller and its approval marks a payoff for BMS's 2020 acquisition of the medicine's developer, MyoKardia. SPONSORED Cisco Meraki Smart Spaces: Enterprises at Scale From Presidio, Cisco Meraki, and Purple AI Join Presidio, Cisco Meraki and Purple AI on Thursday, May 5th from 3PM - 4PM EST to learn how you can transform any location into a highly-intelligent smart space. Three ways tech can help overcome healthcare burnout and staff shortages By Dr. Muthu Alagappan Friday, April 29, 2022 4:37 PM Offloading menial tasks to digital assistants isn't just about a reduction in workload; it allows physicians to refocus their time on what they entered the profession to do—treating patients. Read more » CEO of cardiology startup declares that its tech could potentially cure heart failure By Michael Schroeder Friday, April 29, 2022 1:02 PM Ceryx's device, Cysoni, is designed to pace the heart in rhythm with a person's respiration, so that the heart rate and breathing are synced. This is typically the case for a healthy person, but for someone with heart failure, that link becomes severed, CEO Stuart Plant said. Read more » Potential blockbuster BMS cardio drug gets FDA nod, first in rare heart disease By Frank Vinluan Friday, April 29, 2022 12:36 PM Bristol Myers Squibb drug Camzyos has FDA approval for treating obstructive hypertrophic cardiomyopathy, a rare and potentially fatal heart disorder. The drug is projected to become a blockbuster seller and its approval marks a payoff for BMS's 2020 acquisition of the medicine's developer, MyoKardia. Read more » MedCity Pivot Podcast: A conversation with Buoy Health's chief medical officer In our conversation, Adrienne McFadden, who at one time was a practicing physician, speaks about the evolution of the company to more of a curated matchmaker connecting and guiding people to the best care available. Listen Now! MedCity News   611 Broadway    New York,  NY   10012   United States You received this email because you are subscribed to MedCity Daily Digest from MedCity News. Update your email preferences to choose the types of emails you receive.  Unsubscribe from all future emails